Compare DexCom, Inc. (DXCM) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? DexCom, Inc. trades at $90.51 (market cap $33.79B), while Vanguard Dividend Appreciation Index Fund ETF trades at $246.32. Which is the better fit depends on your goals.
| DXCM | VIG | |
|---|---|---|
Market Cap | $33.79B | — |
Sector | Health | — |
52-Week High | $89.53 | $245.79 |
52-Week Low | $54.84 | $208.67 |
Enterprise Value | $33.24B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
VIG trades at $246.06, up 0.11% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF focuses on dividend growth, with a 1.5% yield and a 20-year streak of dividend increases. Recent news highlights its appeal for long-term income investors, with top holdings like Broadcom driving performance. Support and resistance are tightly clustered around $245–$247.
Outlook remains positive for dividend growth investors, with low expense ratios and quality stock selection. Risks include interest rate sensitivity and market volatility. Analyst sentiment is favorable, emphasizing defensive positioning and long-term wealth building.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
